Related Experiment Videos
[Is regression of atherosclerosis possible?].
D Thomas1, J L Richard, J Emmerich
1Service de cardiologie, groupe hospitalier Pitié-Salpêtrière, Paris.
Archives Des Maladies Du Coeur Et Des Vaisseaux
|October 1, 1992
Summary
Atherosclerosis regression in humans is controversial but achievable. Studies show lipid-lowering therapies, diet, or surgery can reduce atherosclerotic lesions, though clinical benefits require further study.
Area of Science:
- Cardiovascular research
- Medical imaging analysis
- Clinical trial methodology
Context:
- Atherosclerosis regression in animals is established, but human regression remains debated.
- Methodological challenges in human studies include standardized angiographic analysis.
- Previous trials show mixed results regarding atherosclerosis regression and clinical outcomes.
Purpose:
- To evaluate the evidence for atherosclerosis regression in humans.
- To assess the impact of lipid-lowering interventions on atherosclerotic lesions.
- To examine the clinical significance of atherosclerosis regression.
Summary:
- Clinical studies using angiography demonstrate atherosclerosis regression with significant reductions in total and LDL cholesterol.
- Interventions include lipid-lowering drugs (CLAS, FATS, SCOR), diet (Lifestyle Heart Trial), and surgery (POSCH).
- Non-lipid-lowering drugs (calcium antagonists) did not show regression but reduced new lesion formation.
Impact:
- Demonstrating clinical benefits of regression is challenging due to study limitations (duration, sample size, asymptomatic patients).
- Observed modest reductions in cardiovascular events, primarily in symptomatic individuals.
- Lipid factor reduction likely contributes to reduced progression and plaque regression.